Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US02043Q1076
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.82 | |||||
Equity-to-Asset | -0.06 | |||||
Debt-to-Equity | -5.93 | |||||
Debt-to-EBITDA | -12.91 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.3 | |||||
Beneish M-Score | -2.41 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 50.6 | |||||
3-Year EBITDA Growth Rate | 34.2 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 75.15 | |||||
9-Day RSI | 66.48 | |||||
14-Day RSI | 59.89 | |||||
6-1 Month Momentum % | -9.78 | |||||
12-1 Month Momentum % | -27.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.17 | |||||
Quick Ratio | 3.07 | |||||
Cash Ratio | 2.52 | |||||
Days Inventory | 116.08 | |||||
Days Sales Outstanding | 51.55 | |||||
Days Payable | 74.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -0.35 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 83.95 | |||||
Operating Margin % | -8.78 | |||||
Net Margin % | -16.58 | |||||
FCF Margin % | 6.38 | |||||
ROA % | -9.08 | |||||
ROIC % | -17.46 | |||||
ROC (Joel Greenblatt) % | -27.03 | |||||
ROCE % | -7.06 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.83 | |||||
Price-to-Free-Cash-Flow | 171.96 | |||||
Price-to-Operating-Cash-Flow | 111.69 | |||||
EV-to-EBIT | -93.5 | |||||
EV-to-Forward-EBIT | -44.64 | |||||
EV-to-EBITDA | -182.98 | |||||
EV-to-Forward-EBITDA | -49.92 | |||||
EV-to-Revenue | 9.21 | |||||
EV-to-Forward-Revenue | 9.77 | |||||
EV-to-FCF | 144.27 | |||||
Price-to-Median-PS-Value | 0.11 | |||||
Earnings Yield (Greenblatt) % | -1.07 | |||||
FCF Yield % | 0.66 |